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Abstract: Three known bromophenols, 2,3-dibromo-4,5-dihydroxybenzylaldehyde (1), 
2,2′,3-tribromo-3′,4,4′,5-tetrahydroxy-6′-hydroxymethyldiphenylmethane (2) and bis(2, 
3-dibromo-4,5-dihydroxylbenzyl) ether (3), and one new one, 5,5″-oxybis(methylene)bis 
(3-bromo-4-(2′,3′-dibromo-4′,5′-dihydroxylbenzyl)benzene-1,2-diol) (4), were isolated 
from an extract of the red alga, Vertebrata lanosa. The antioxidant activity of these four 
bromophenols was examined using one biochemical and two cellular assays: Oxygen 
Radical Absorbance Capacity (ORAC), Cellular Antioxidant Activity (CAA) and Cellular 
Lipid Peroxidation Antioxidant Activity (CLPAA) assays. Compound 2 distinguished itself 
by showing potent activity, having a better antioxidant effect than luteolin in both the CAA 
and CLPAA assays and of quercetin in the CLPAA assay. Although several bromophenols 
are known to be potent antioxidants in biochemical assays, this is the first time their 
cellular antioxidant activity has been demonstrated. 








Marine macroalgae are known to contain structurally diverse natural compounds with a range of 
different biological activities [1]. One class of compounds derived from macroalgae are known as 
bromophenols (BPs). The BPs are biosynthesized from polyphenols by bromoperoxidases in the 
presence of hydrogen peroxide and bromide [2]. They are common marine secondary metabolites [3], 
although the algal content seems to vary with season [4] and tide [2]. Different biological activities 
have been reported for the BPs; among these are antioxidant, antimicrobial, anticancer, anti-diabetic 
and anti-thrombotic effects, which make them interesting compounds in the development of new 
pharmaceutical agents [3].  
Structurally, the BPs contain one or several benzene rings and a varying number of bromine and 
hydroxyl-substituents [3]. The relationship between the molecular structure of some BPs and their 
antioxidant effect have previously been investigated [5], and the trend is that the activity is improved 
by both an increased number of hydroxyl groups and conjugations [6–8]. According to the review of 
Liu and co-workers, the 1,4-dihydroxy arrangement seems to be favorable for antioxidant activity, 
while bromination appears to be of little importance [3]. When natural BPs were compared to their 
corresponding debrominated compounds, it was discovered that bromination even decreased the 
antioxidant effect [9].  
The first marine BP was isolated from the red alga Polysiphonia morrowii in 1955 [10], and 
subsequently several BPs have been isolated and identified from red, brown and green algae [3]. Some 
species of red algae have concentrations of BPs up to 2590 ng/g [2], and more than 30 monoaryl and 
diaryl BPs have been discovered in the Rhodomelaceae family [11]. Marine alga is not the only marine 
source of these metabolites, as they are also found in ascidians and sponges [3]. The red alga 
Vertebrata lanosa is a member of the family Rhodomelaceae. Several synonyms are known for this 
alga, the name Polysiphonia lanosa has also been widely used. The alga is commonly distributed in 
Europe, and it is also found in North America, Canada, tropical and subtropical Western  
Atlantic [12]. Crude extracts of V. lanosa have been reported to show high antioxidant activity in 
biochemical assays in addition to having a high phenolic content [13].  
Antioxidants serve as a defense against free radicals, such as reactive oxygen species (ROS) and 
reactive nitrogen species (RNS). ROS and RNS form naturally during many metabolic processes, when 
well regulated, they contribute toward maintaining homeostasis in normal healthy cells and work as 
signaling molecules [14]. However, the level of free radicals can increase if this balance is lost, which 
can happen in response to xenobiotics or environmental stress. When the balance is shifted towards 
pro-oxidants, a state of oxidative stress occurs, this condition can be a contributing factor to the 
development of several medical conditions, such as cardiovascular diseases, including atherosclerosis, 
various types of cancer, diabetes and neurodegenerative diseases, like Parkinson’s and Alzheimer’s 
disease. Cells have several protective mechanisms against the harmful effects of ROS and RNS, both 
enzymatic (e.g., superoxide dismutases, catalase and glutathione peroxidase) and nonenzymatic  
(e.g., GSH, NADPH, α-tocopherol and ascorbic acid) [14–16]. These antioxidant mechanisms work to 
prevent, intercept and repair the damage caused by the free radicals [14]. 
Recently, a study was published where the antioxidant activities of 19 naturally occurring BPs were 
reported, six of which were new, from the alga Rhodomela confervoides. Most of the isolated 
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compounds showed a significant antioxidant activity against 2,2-Diphenyl-1-picrylhydrazyl (DPPH) 
and 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radicals [5]. At present, 
approximately 30 BPs with antioxidant activity have been reported from marine algae. The published 
studies have only investigated the activity in vitro, mainly determined by the DPPH radical  
scavenging method [3].  
Thus, the purpose of the present study was to further examine the antioxidant potential of one new 
and three known BPs isolated form V. lanosa. In addition to a biochemical assay, Oxygen Radical 
Absorbance Capacity (ORAC), two cellular assays were included; Cellular Antioxidant Activity 
(CAA) assay and Cellular Lipid Peroxidation Antioxidant Activity (CLPAA) assay. The two latter 
methods allowed us to explore the bioavailability of the compounds, particularly if they were able to 
pass cellular membranes.  
2. Results and Discussion 
2.1. Isolation and Characterization  
Compounds 1–4 (Scheme 1) were all isolated from the red alga V. lanosa collected in Oldervik, 
Ullsfjorden, Norway. Bioactivity screening of the algal extract indicated both anticancer and 
antioxidant effects. Brominated compounds were isolated by mass guided preparative HPLC, followed 
by structure characterization of compounds 1–4 using high resolution MS and NMR.  
Scheme 1. Molecular structures of compounds 1–4. Proton and carbon denotations are 
given (color codes are used for compounds 2 (black) and 4 (blue) to distinguish them in the 
NMR spectra (Figures S2 to S5 in the Supplementary Material)).  
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2.2. Identification of Compound 4 
The NMR spectra of compound 4 was found to be near identical to those of the previously reported 
compound 2, with the exception of a downfield shift of C6 of approximately 10 ppm and an apparent 
long range 
3
JCH from C6 to the directly bound H6 in the HMBC spectrum (see Figures S2 to S5 in the 
Supporting Material). The superimposed HSQC and HMBC spectra display overlapping correlations in 
both HSQC and HMBC for C6H6. This becomes possible only if compound 4 is the symmetric dimer 




JC6'H6 couplings to form a correlation in the 
13
C-HMBC, 










H chemical shifts, 
in addition to the observed HMBC correlations of compound 4 (Scheme 1), are summarized in  
Table 1.  
Table 1. NMR spectroscopic data (600 MHz, methanol-d4) for compounds 2 and  
4 referenced against the solvent residual peak for methanol-d4: 
1
H = 3.31 ppm,  
13
C = 49.00 ppm. For proton and carbon denotations, see Scheme 1.  
 compound 2  compound 4 
# δC, type δH HMBC (H → C) 
a
  # δC, type δH HMBC (H → C) 
a
 
1 132.62, C    1′″ 132.82, C   
2 116.29, C    2′″ 116.39, C   
3 114.19, C    3′″ 114.24, C   
4 143.76, C    4′″ 143.68, C 6.84,s 2, 3, 6, 7  
5 146.20, C    5′″ 146.08, C   
6 115.03, CH 6.07,s 8, 9, 11, 12, 14  6′″ 115.16, CH 6.03,s 8, 9, 11, 12, 14 
7 39.65, CH2 4.13,s 5, 7, 9, 10, 11, 12, 14  7′″ 39.82, CH2 4.05,s 5, 7, 9, 10, 11, 12, 14 
1′ 128.97, C    4″ 130.64, C  4, 5, 6', 7 
2′ 115.49, C    3″ 116.20, C   
3′ 143.76, C    2″ 144.44, C  8, 9, 11, 12, 14 
4′ 145.82, C    1″ 145.54, C   
5′ 115.55, CH 6.96,s 2, 3, 6, 7  6″ 117.25, CH 6.84,s 2, 3, 6, 7  
6′ 133.48, C    5″ 130.17, C   
7′ 63.21, CH2 4.36,s 4, 5, 7  7″ 71.94, CH2 4.20,s 4, 5, 6', 7 
a HMBC correlations, optimized for 8 Hz, are from proton(s) to the indicated carbon. 
Compound 4 has not previously been reported. However, we cannot exclude that it might be an 
artefact of the extraction and purification process. In 
1
H NMR spectra for compound 2, it was observed 
that compound 4 formed gradually during isolation, from 0.17 mol% in the beginning to 0.25 mol% at 
the end. In the presence of acid and water, as in a protonated aqueous mixture after purification by 
HPLC, dimerization of compound 2 might occur. Dehydration of benzyl alcohol to dibenzyl ether has 
previously been reported [17]. Benzyl alcohol is less sterically hindered than compound 2 and does not 
contain any substituents on the aromatic ring. Nevertheless, the data presented indicates that 
condensation between two aromatic compounds containing primary alcohols is possible. An 
experiment was performed, where compound 2 was dissolved in H2O with 0.1% formic acid to imitate 
the conditions after HPLC. 
1
H NMR data were acquired before and after storage at 4 °C for seven 
days. Peaks corresponding to protons on carbon 5′, 6, 7′ and 7 (for compound 2) and (6,6″), (6′,6′″),  
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(7,7″) and (7′,7′″) (for compound 4) were used to examine if a dimerization had occurred. When ratios 
of peak intensities between compounds 2 and 4 were compared, an alteration from 3.6:1 mol% to  
2.6:1 mol% was found after seven days of storage. This demonstrates that compound 2 is acid labile 
and can convert to compound 4 upon prolonged storage in acidic water. Hence, compound 2 should 
not be kept in a protonated aqueous environment for a long time, as dimerization reduces the 
antioxidant effect.  
2.3. Antioxidant Activity 
The mechanisms behind antioxidant protection of cells are many and complex; they can be both 
enzymatic and non-enzymatic, one single assay cannot reflect the complex interactions that occur 
between antioxidants and their targets in vivo [18]. It is therefore necessary to apply several 
complimentary assays in order to assess the biological relevance of an antioxidant. In this study, we 
used the ORAC assay to see if the compounds had antioxidant activity in general and the cellular 
assays CAA and CLPAA were included to get complimentary information about bioavailability.  
2.3.1. Antioxidant Assay for Oxygen Radical Absorbance Capacity (ORAC) 
This biochemical assay measures the oxidative degeneration of fluorescein and is based on the 
procedure by Huang et al. [19]. Antioxidants are able to protect fluorescein from degradation after 
exposure to 2,2′-azobis(2-methylpropioanamidine) dihydrochloride (AAPH) radicals, and this results 
in a reduction of fluorescence.  
Quercetin and luteolin are known to have antioxidant activity and are commonly used as reference 
compounds. Wolfe and co-workers classifies them as having a moderate effect in the ORAC assay [20], 
it has also been reported by our research group [21]. When examined in this study, quercetin and 
luteolin displayed activities of 7 and 10 µM Trolox equivalents (TE), respectively, at 1 μg/mL.  
All of the compounds showed a dose-dependent activity. The antioxidant activity was found to be 
highest for compound 2, followed by compound 4, as seen in Figure 1. Compounds 1 and 3 were 
found to be the least active in the assay. Although compound 2 was the most active of the compounds 
isolated, it was not as active as quercetin and luteolin.  
2.3.2. Antioxidant Assay for Cellular Antioxidant Activity (CAA) 
The assay was performed based on the procedure of Wolfe and Liu (2007) [22].  
Compounds found active in the CAA assay are intracellular antioxidants. They have the ability to 
penetrate the cell membrane and reduce the oxidation of 2′7′-dichlorofluorescin (DCFH), a reaction 
activated using a radical initiator, like AAPH, to the fluorescent molecule, DCF.  
In this assay, quercetin and luteolin were able to inhibit the oxidation of DCFH, by 92% and 58%, 
respectively, at 10 µg/mL. These two known antioxidants have previously been reported to have a high 
antioxidant activity in the CAA assay, both by our research group and others [20,21]. As seen by 
Figure 2, compound 2 shows a dose-dependent activity, capable of inhibiting oxidation at 
concentrations as low as 10 µg/mL (68%). Thus, compound 2 has a significantly better effect than 
luteolin but was less active than quercetin at the same concentration, making it a promising 
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intracellular antioxidant. Compounds 3 and 4 exhibited a significant inhibition at the highest 
concentration, while compound 1 did not show activity at any of the concentrations tested (Figure 2). 
Figure 1. Oxygen Radical Absorbance Capacity (ORAC): oxidative degeneration of 
fluorescein after the addition of 2,2′-azobis(2-methylpropioanamidine) dihydrochloride 
(AAPH), measured in μM trolox equivalents. Compounds 1–4 were examined in 
concentrations of 1, 5, 10, 25 and 50 μg/mL. The bars indicate mean Trolox equivalents 
(TE) with SEM; n = 4 from two independent runs. The highest concentration tested for 
compound 3 was 25 µg/mL.  
 
Figure 2. Cellular Antioxidant Activity (CAA): percent inhibition of oxidative degeneration 
of 2′7′-dichlorofluorescin (DCFH) to DCF inside HepG2 cells after the addition of AAPH 
and compounds 1–4. Concentrations of 1, 5, 10, 20 and 50 µg/mL were tested. The bars 
indicate mean percent inhibition, with SEM; n = 4 from two independent runs.  
 
* The highest concentration tested was 30 μg/mL, not 50 μg/mL. 
2.3.3. Cellular Lipid Peroxidation Antioxidant Activity (CLPAA) Assay 
The assay was performed based on the procedure of Pap et al. [23]. It is used to quantify lipid 
peroxidation within cell membranes and, to a lesser extent, the plasma membrane. A C11-BODIPY 
probe is distributed heterogeneously throughout cellular membranes and changes from red to green 
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when oxidized, a reaction activated using a radical initiator, like cumene hydroperoxide (cumOOH), 
and the antioxidant activity is measured as an increase of green fluorescence [24].  
Quercetin and luteolin gave inhibitions of 35% and 34%, respectively, at 5 μg/mL in this assay. At 
the same concentration, compound 2 was able to prevent oxidation of the probe at 45%, as illustrated 
in Figure 3. Thus, the ability to prevent lipid peroxidation within the cell membranes was found to be 
greater for compound 2 than the known antioxidants in this assay. 
Compounds 3 and 4 also showed antioxidant activity, at the two highest concentrations of the 
former and at the highest concentration of the latter. Compound 1 had a weak activity in the CLPAA 
assay compared to quercetin and luteolin.  
Figure 3. Cellular Lipid Peroxidation Antioxidant Activity (CLPAA): percent inhibition of 
oxidative degeneration of the C11-BODIPY probe in HepG2 cells after the addition of 
cumene hydroperoxide (cumOOH) and compounds 1–4. Concentrations of 1, 5, 10, 20 and 
50 μg/mL were tested. The bars indicate mean percent inhibition with SEM; n = 4 from 
two independent runs.  
 
* The highest concentration tested was 30 μg/mL, not 50 μg/mL. 
2.4. Cytotoxicity  
Cytotoxicity was examined with a viability assay using a cell line of normal human lung  
fibroblasts (MRC-5). The compounds were tested at 5, 25 and 50 μg/mL. Compound 3 was toxic at  
25 μg/mL, and it was concluded that the highest concentration to be used in the cellular antioxidant 
assays should be 30 μg/mL for compound 3 (data not shown). Compounds 1, 2 and 4 did not show 
cytotoxicity at the concentrations tested.  
2.5. Advantages of Complementing Biochemical Assays with Cellular Ones  
Biochemical assays are commonly used to examine antioxidant activity. As noted in the review of 
Liu and co-workers, antioxidant activity is usually determined by the DPPH radical scavenging 
method [3]. This is a fast and easy way to determine antioxidant activity, but does not take into 
account the complex environment of cells, like bioavailability and membrane permeability.  
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The use of cellular assays in addition to biochemical ones have also previously been utilized by our 
research group [21]. Information obtained by the cellular assays is advantageous, as biological systems 
are much more complex than chemical mixtures. Cellular assays detect only the antioxidants that can 
penetrate the cell membrane of living cells and inhibit oxidation within the cells. Hence, these assays 
give additional information on bioavailability, uptake, metabolism and interactions with cellular 
components, which is more realistic compared to the situation in vivo [25]. When including the CAA 
and CLPAA assays in our study, we gained supplementary information regarding the pharmacokinetic 
properties of compound 2, which was found to be able to penetrate the cell membranes and work as an 
intracellular antioxidant, in addition to preventing lipid peroxidation within cell membranes.  
Antioxidant activity in biochemical and cellular assays are not always equivalent. A study 
comparing antioxidant activities of flavonoids between the ORAC and CAA assays did not find a 
significant correlation. Although quercetin and luteolin had moderate activity in the ORAC assay, they 
both showed a high cellular antioxidant activity. It was concluded that the absence of correlation 
probably was due to the biological mechanisms of the CAA assay [20]. We found the same to be true 
for compound 2, as it was moderately active in the ORAC assay, while displaying a high activity in the 
CAA assay.  
2.6. Assessment of Purity  
Compound 2 was not pure when examined in the assays, but existed in a mixture with compound 4 
in the ratio of 4:1. Purification proved to be difficult, due to the dimerization of compound 2 into 
compound 4, as shown by the experiment of storing the former in acidic water for one week (see 
Section 2.2). Although not completely pure, we conclude that the antioxidant effect of compound 2 is 
genuine based on compound 4 displaying a poorer antioxidant effect. Due to this impurity, the actual 
concentrations of compound 2 examined are likely to be lower than presented here. Thus, compound 2 
is possibly effective at even lower concentrations.  
When stored in methanol, the methyl ether of compound 2 was observed in the 
1
H NMR spectrum. 
A similar incident has also previously been reported by another research group [26]. The methyl ether 
of compound 2 was removed in the following isolation.  
3. Experimental Section  
3.1. Material 
Compounds 1–4 were all isolated from the red alga Vertebrata lanosa, collected by the marine 
biobank Marbank in Oldervik, Ullsfjorden (Norway, spring 2010). The alga was freeze-dried and 
ground before extraction with water, followed by extraction of the remaining organic material using 
dichloromethane:MeOH 1:1. The extracts were stored at −24 °C until usage. Only the organic extract 
was used, due to a larger content of the target compounds.  
3.2. Sample Preparation  
The extract was dissolved in hexane and partitioned twice against MeOH at room temperature. The 
MeOH phase was reduced to dryness in vacuo at 40 °C, resuspended in purified water and partitioned 
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twice against EtOAc at room temperature, followed by the removal of volatiles in vacuo at 40 °C and 
SpeedVac. The EtOAc phase contained a larger concentration of the target compounds and was, thus, 
used further in the purification process. 
3.3. Purification  
HPLC purification was performed using a Waters (Milford, MA, USA) purification system 
controlled by MassLynx version 4.1. The purification system consisted of a Waters 600 pump, a 
Waters 3100 mass spectrometer (in negative mode, with an ESI-electrospray source), a Waters 2996 
photo diode array detector and a Waters 2767 sample manager. Samples were injected in  
1:1 H2O/can, and fraction collection was triggered when the intensity of the target mass exceeded the 
threshold specified in the method. The compounds were isolated on a Waters XTerra  
MS-C18 (10 × 250 mm, 5 µm) column and a Waters XSELECT CSH (10 × 250 mm, 5 µm) column. 
Gradients of H2O with 0.1% FA (A) and acetonitrile with 0.1% FA (B) were used at a flow rate of  
6 mL/min and optimized for each compound (compound 1: 50%–55% B over 10 min; compounds 2 
and 4: 50%–60% B over 10 min; compound 3: 65%–85% B over 25 min).  
3.4. Accurate Mass Determination and Elemental Composition of Compounds 1–4 Using High 
Resolution ESI-MS 
Accurate mass determination was performed using a Waters (Milford, MA, USA) UPLC-ToF-MS 
system controlled by MassLynx version 4.1. The UPLC-ToF-MS system consisted of a Waters LCT 
Premier and a Waters Acquity UPLC. The compounds were separated on an Acquity UPLC

 BEH C18 
(2.1 × 50 mm, 1.7 μm) column. Gradients of H2O with 0.1% FA (A) and acetonitrile with 0.1% FA (B) 
were used at a flow rate of 0.350 mL/min (20%–100% B over 3.5 min). 
Possible elemental compositions of compounds 1–4 were calculated using accurate MS, while 
ChemDraw Pro V 12.0.2 was used to determine the calculated accurate masses.  
The calculated elemental compositions were compared with the literature and the information used 
in combination with NMR data to elucidate the structures of compounds 1–4.  
Compound 1: m/z 292.8448 [M − H]
+
, calculated for C7H4Br2O3 292.8448. Compound 2: m/z 
494.8067 [M − H]
+
, calculated for C14H11Br3O5 494.8078. Compound 3: m/z 572.7182 [M − H]
+
, 
calculated for C14H10Br4O5 571.7103. Compound 4: m/z 972.6160 [M − H]
+
, calculated for 
C28H20Br6O9 972.6129. 
3.5. Identification of Compounds 1–4 by NMR  
NMR data were used for structure confirmation of compounds 1–3 and elucidation of compound 4. 
The NMR experiments were acquired on an Agilent (Varian) Inova spectrometer operating at 599.934 




C, respectively, using a cryogenically cooled inverse detection HCN 
probe with enhanced proton channel (2nd generation). Typically, 16k data points were acquired for the 
1D 
1
H experiments using 90° reading pulses, 5 seconds of relaxation delay and 64 transients. Data 
matrices of 1440 × 200 and 1440 × 256 complex points were acquired for the gradient selected edited 
HSQC and absolute value HMBC, respectively, using 32 transients. For carbon 1D spectra, 32k complex 
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data points were acquired, using 45° reading pulses, 1-second relaxation delay and 20,000 transients, 
applying 
1
H decoupling during both relaxation and acquisition time. All spectra were acquired at  





C, respectively. All experiments were referenced to the residual solvent peak; 3.34 ppm 
for methanol-d4 and 7.26 ppm for CDCl3 [27].  
Compound 1 was identified as 2,3-dibromo-4,5-dihydroxybenzylaldehyde, published for the first 
time by Katsui and co-workers [28]. 
1
H NMR (600 MHz, methanol-d4) δH 7.34 (s, 1H), 10.12 (s, 1H). 
13
C NMR (600 MHz, methanol-d4) δC n/a (s, C-3), 152.70 (s, C-4), 146.37 (s, C-5), 114.02 (d, C-6), 
126.81 (s, C-1), 192.38 (d, C-7), 122.04 (s, C-2). Impurities of other related compounds (15 mol%) and 
lipids (25–50 mol%) were present.  
Compound 2 was identified as 2,2′,3-tribromo-3′,4,4′,5-tetrahydroxy-6′-hydroxymethyldiphenyl 




C NMR, see Table 1. It 




C NMR values for compound 4 are 
presented in Table 1). Impurities of other related compounds (less than 5 mol%) and lipid (6–14 mol%) 
were present. 
Compound 3 was identified as bis(2,3-dibromo-4,5-dihydroxylbenzyl) ether, first published by 
Kurihara and coworkers [29]. 
1
H NMR (600 MHz, CDCl3) δH 5.46 (s, OH), 5.60 (s, OH), 7.16 (s, 1H), 
4.61 (s, 1H). 
13
C NMR (600 MHz, CDCl3) δC 113.20 (s, C-3′), 140.60 (s, C-4′), 143.41 (s, C-5′), 
115.11 (d, C-6′), 131.67 (s, C-1′), 72.64 (d, C-7′), 113.80 (s, C-2′). Impurities of other related 
compounds (10 mol%) and lipid (less than 5%) were present. 
 
Compound 4 was identified as 5,5″-oxybis(methylene)bis(3-bromo-4-(2′,3′-dibromo-4′,5′-dihydroxyl 




H and HMBC data are presented in  
Table 1. High resolution MS spectra (Figure S1) and the following NMR spectra are attached in  
the supplementary material: 
1
H (Figure S2), 
13
C (Figure S3), superimposed HSQC and HMBC  
(Figure S4). Compound 4 existed in a mixture with compound 2 in the ratio of ~1:1.5. Impurities of 
lipid (20–40 mol%) were present.  
3.6. Preparation of Solutions 
A 20 mg/mL stock solution in DMSO was prepared for each compound. Working solutions were 
diluted in RPMI-1640 for the cell viability assay, while in MilliQ water for the remaining assays. Final 
test concentrations for the cell viability assay were 5, 25 and 50 μg/mL. In the ORAC assay, final test 
concentrations were 1, 5, 10, 25 and 50 μg/mL, while they were 1, 5, 10, 20 and 50 μg/mL for CAA 
and CLPAA. An exception was compound 3, where 30 μg/mL was the highest concentration in the 
antioxidant assays.  
3.7. Cell Culture and Seeding  
MRC-5 (human fetal lung; ATCC, CCL-171™) cells were grown in RPMI-1640 and HepG2 
(human hepatocellular liver carcinoma; ATCC HB-8065™) in MEM-Earle’s medium (F0325); both 
media were supplemented with fetal bovine serum (10%, S0115), non-essential amino acids  
(1%, K0293), sodium pyruvate (1 mM, L0473), L-alanyl-L-glutamine (2 mM, K0302) and gensumycin 
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(10 μg/mL, A2712) and incubated at 37 °C with 5% CO2. All incubations were performed at 37 C 
with 5% CO2. Media and supplements were all from Biochrom (Berlin, Germany).  
3.8. Cytotoxicity 
Cell viability was determined by a colorimetric [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy 
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) assay. 
MRC-5 cells were seeded in 96-well microtiter plates (Nunc 167008) at a concentration of  
2000 cells/well and incubated for 24 h. After the media was removed, RPMI-1640 with 10% FBS, in 
addition to the compounds in triplicate, were added. The plate was then incubated for 72 h at 37 °C in 
a humidified atmosphere of 5% CO2. At the end of the exposure time, CellTiter 96
®
 AQueous One 
Solution Reagent (Promega, Madison, WI, USA) was added to each well and the plate incubated for  
1 h. Absorbance was measured at 485 nm in a DTX 880 Multimode Detector (Beckman Coulter,  
CA, USA).  
Cells in RPMI-1640 medium were used as negative control and cells treated with Triton
®
 X-100 
(Sigma-Aldrich) reagent as positive control. Relative cell survival was determined by using the 
measured optical density (OD), calculated as: cell survival (%) = (OD treated well − OD positive 
control)/(OD negative control − OD positive control) × 100.  
3.9. Antioxidant Assay for Oxygen Radical Absorbance Capacity (ORAC) 
The assay was performed based on the procedure of Huang et al [19].  
The method was carried out in black 96-well plates (Nunc 7350004). Fluorescence was recorded 
using a 1420 Victor3 Plate Reader (Perkin Elmer, MA, USA, with the software, Workout 2.0, from 
Dazaq Solutions Ltd.) at 37 °C. The compounds, and Trolox (Sigma-Aldrich, 238813) at final 
concentrations of 0–17 μM included to construct a standard curve, were added in duplicate, followed 
by the addition of fluorescein (Fluka, 46960) (final concentration of 55 nM). Quercetin dehydrate 
(Sigma-Aldrich, 200595) and luteolin (Cayman #10004161) (final concentrations of 1, 5, 10, 25 and 
50 μg/mL) were used as antioxidant controls. After a 15-minute incubation, AAPH (2,2′-azobis 
(2-methylpropioanamidine) dihydrochloride; Sigma-Aldrich, 440914) (final concentration of 16 mM) 
was added to each sample. Fluorescence was recorded 25 times with a 70-second delay between the 
repeats. Excitation (486 nm) and emission (520 nm) were used. Phosphate buffer (PB) was used as a 
blank for the 0 μM Trolox sample. The area under the curve (AUC) was calculated with the AUCblanc 
values subtracted. A standard curve was made using the Trolox values, and Trolox equivalents of the 
samples were calculated. Results were expressed as μM Trolox equivalents (TE). Total reaction 
volume was 210 µL (where 25 µL was the volume of the test compound). All reagents were dissolved 
in 75 nM PB (pH 7.4), and the incubations were at 37 °C.  
3.10. Antioxidant Assay for Cellular Antioxidant Activity (CAA) 
The assay was performed based on the procedure of Wolfe and Liu (2007) [22].  
The method was carried out in black 96-well plates (#3603, Corning, NY, USA) with an optical 
bottom. Fluorescence was recorded using the same plate reader, software and temperature as for the 
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ORAC assay. HepG2 cells were seeded at a density of approximately 80,000 cells/well and incubated 
overnight. Cells were then incubated with DCFH-DA (2′7′-dichlorofluorescin diacetate; Fluka, 35847) 
(final concentration of 25 μM) and the test compounds in duplicate for 1 h. Quercetin and luteolin 
(final concentrations of 1, 5, 10, 20 and 50 (or 30) μg/mL) were used as antioxidant controls. After 
incubation, Hank’s saline solution without phenol red (Biochrom, BCHRL2035) supplemented with 
AAPH (final concentration of 600 μM) was added to all the wells, except for the negative control. To 
these wells was added Hank’s saline solution without AAPH. The plate was immediately placed in the 
plate reader and fluorescence recorded; excitation of 485 nm and emission of 520 nm were used. The 
plate was incubated for 1 h before a second reading. Cells were washed with PBS between the addition 
of new reagents. The total reaction volume was 100 μL (where 20 μL was the volume of the test 
compound). The incubations were at 37 °C in a humidified atmosphere of 5% CO2.  
Cells in MEM Earle’s medium were used as negative control and cells treated with AAPH as 
positive control. The oxidative degeneration of DCFH-DA to DCF was calculated as:  
activity (%) = (fluorescence treated well − fluorescence positive control)/(fluorescence negative  
control − fluorescence positive control) × 100. Fluorescence value: fluorescence reading  
2 − fluorescence reading 1. Inhibition (%) was calculated as: 100% − activation%. The results are 
presented as relative values compared to the positive and negative controls, with and  
without AAPH, respectively. 
3.11. Cellular Lipid Peroxidation Antioxidant Activity (CLPAA) Assay 
The assay was performed based on the procedure of Pap et al. [23]. 
The method was carried out in the same plates as in the CAA assay. Fluorescence was recorded 
using the same plate reader, software and temperature as for the ORAC and CAA assays. HepG2 cells 
were seeded and incubated overnight, as described in the CAA assay. The cells were labelled with  
5 µM C11-BODIPY (#D3861, Invitrogen, Eugene, OR, USA) for 30 min, following the addition of 
compounds at various concentrations and incubating for 1 h. Quercetin and luteolin (final 
concentrations of 1, 5, 10, 20 and 50 (or 30) μg/mL) were used as antioxidant controls. Cumene 
hydroperoxide (cumOOH, 247502, Sigma-Aldrich, St. Louis, MO, USA) (at a final concentration of 
50 µM) in Hank’s saline solution without phenol red was added to initiate lipid peroxidation. The 
addition was done to all the wells, except the ones for negative control, to which were added Hank’s 
saline solution without phenol red and without cumOOH. The plate was immediately placed in the 
plate reader. Both red [590 (excitation)/632 (emission)] and green [485 (excitation)/520 (emission)] 
fluorescence was recorded during ~1 h at 37 °C. Cells were washed with PBS between additions of 
new reagents. The total reaction volume was 100 μL (where 20 μL was the volume of the test 
compound). All incubations were carried out at 37 °C in a humidified atmosphere of 5% CO2. 
Cells in MEM Earle’s medium were used as negative control and cells treated with cumOOH as 
positive control. The oxidative degeneration of C11-BODIPY was calculated based on the increase of 
green fluorescence as: activity (%) = (fluorescence treated well − fluorescence positive control)/ 
(fluorescence negative control − fluore scence positive control) × 100. Inhibition (%) was calculated 
as: 100% − activation%. The results are presented as relative values compared to the positive and 
negative controls, with and without cumOOH, respectively. 
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4. Conclusions  
Cellular antioxidant effects for the bromophenol, 2,2′,3-tribromo-3′,4,4′,5-tetrahydroxy-6′-hydroxy 
methyl-diphenylmethane (compound 2), have been reported for the first time. The fact that the 
compound was active in the CAA assay demonstrates that it enters cells, and as it was also active in 
the CLPAA assay, it shows the ability to decrease lipid peroxidation in cell membranes. Compound 2 
was a better antioxidant than luteolin in both cellular assays and of quercetin in the CLPAA assay, and 
it was active well below the cytotoxic concentration in all assays.  
The structure of compound 4 and its activity in biological assays is reported for the first time, and 
compared to quercetin and luteolin, it showed a weak antioxidant activity at 50 μg/mL in all the assays 
(Figures 1–3). The possibility of being an artefact of the extraction and purification process has  
been discussed.  
Only a few studies have been reported on structure-activity relationships (SARs) for BPs, and the 
ones published are all from in vitro biochemical assays [3]. Hydroxyl substitution, a 1,4-dihydroxy 
arrangement, conjugation and bromination are all factors believed to influence the antioxidant activity 
of BPs in these assays. Results show that, more extensively, hydroxyl substitution increases 
antioxidant activity of BPs in DPPH radical scavenging assays [3,6–8,30,31]. This corresponds well 
with the results from our cellular assays, where compound 2, having one hydroxyl substituent more, 
had a greater antioxidant activity than compound 3. However, compound 4 contained three hydroxyl 
substituents more than compound 2, but was found to be less active than the latter. An explanation for 
this might be that compound 4 is a larger molecule, which can influence the cellular uptake. The  
1,4-dihydroxy arrangement has been reported to be very suitable for antioxidant activity, and 
compound 2 resembles such an arrangement, having a hydroxyl and a hydroxymethyl in para position 
to each other [3,32]. The degree of conjugation is proposed as an important factor in increasing the 
antioxidant activity of BPs [3]. Nevertheless, compound 2 does not have a higher degree of 
conjugation, so this does not explain the results in the present study. Bromination of BPs has also been 
investigated in DPPH radical scavenging assays. The antioxidant activity was reported both as 
decreasing, when compared to corresponding debrominated compounds, and as slightly increasing, 
when compared to corresponding chlorinated compounds. Liu and co-workers, therefore, concluded 
that bromination seemed to be of little importance for the antioxidant activity of BPs [3,9,31]. 
Halogenation of polar molecules is a known way to increase their lipophilicity and, consequently, 
increase their bioavailability [33]. Thus, although bromination was found not to be of importance for 
antioxidant activity in biochemical assays, it might influence the bioavailability of compounds. To be 
active in cellular assays, the compounds have to penetrate the cell membrane, and the ability to do so is 
influenced by their size, solubility, polarity and charge. We believe that the poor activity of  
compound 4 in the cellular assays is due to its larger size compared to compound 2. 
This present identification of cellular antioxidant activity of structurally related BPs can be used as 
a starting point for SAR studies, which are more relevant to in vivo conditions, taking into account 
factors like bioactivity and membrane permeability. The cellular assays can be used to, at an early 
stage, exclude compounds lacking the ability of penetrating membranes and, hence, do not have an 
effect in vivo.  
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